Mycobacterium abscessus subsp. abscessus Pulmonary Disease: Fatal Case in an Immunocompetent Patient
Abstract
Nontuberculous mycobacterial pulmonary disease in low-risk patients is rare and typically indolent. We report a case of Mycobacterium abscessus complex (MABC) pulmonary disease in a 71-year-old immunocompetent Italian man who presented with mild dyspnoea that markedly worsened following SARS-CoV-2 infection three months before admission. High-resolution CT showed diffuse small, irregular, predominantly consolidative opacities with peripheral bronchial thickening. Extensive investigations for tuberculosis, fungal infection, other pathogens, and malignancy were negative. Respiratory cultures subsequently yielded MABC, and molecular testing identified a functional erm(41) gene conferring inducible macrolide resistance, consistent with M. abscessus subsp. abscessus. Guideline-based multidrug therapy with intravenous amikacin, tedizolid, clofazimine, and moxifloxacin was initiated. Nephrotoxicity required substitution of intravenous amikacin with an inhaled formulation, followed by ototoxicity and further modification with tigecycline. Despite these adjustments, cultures remained persistently positive. Severe gastrointestinal intolerance and progressive weight loss ultimately led to treatment discontinuation and home oxygen therapy. One year after diagnosis, imaging revealed new cavitary lesions with advanced bilateral disease. The patient died from respiratory failure and severe cachexia. This case shows that MABC infection may follow an aggressive, life-threatening course even…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.